PT - JOURNAL ARTICLE AU - Middelkoop, Keren AU - Micklesfield, Lisa K AU - Walker, Neil AU - Stewart, Justine AU - Delport, Carmen AU - Jolliffe, David A AU - Mendham, Amy E AU - Coussens, Anna K AU - van Graan, Averalda AU - Nuttall, James AU - Tang, Jonathan C Y AU - Fraser, William D AU - Cooper, Cyrus AU - Harvey, Nicholas C AU - Hooper, Richard L AU - Wilkinson, Robert J AU - Bekker, Linda-Gail AU - Martineau, Adrian R TI - Influence of vitamin D supplementation on bone mineral content, bone turnover markers and fracture risk in South African schoolchildren: multicentre double-blind randomised placebo-controlled trial (ViDiKids) AID - 10.1101/2023.05.18.23290153 DP - 2023 Jan 01 TA - medRxiv PG - 2023.05.18.23290153 4099 - http://medrxiv.org/content/early/2023/05/19/2023.05.18.23290153.short 4100 - http://medrxiv.org/content/early/2023/05/19/2023.05.18.23290153.full AB - BACKGROUND Randomised controlled trials (RCT) to determine the influence of vitamin D on bone mineral content (BMC) and fracture risk in children of Black African ancestry are lacking.METHODS We conducted a sub-study nested within a Phase 3 RCT of weekly oral supplementation with 10,000 IU vitamin D3 in HIV-uninfected Cape Town schoolchildren of Black African ancestry aged 6-11 years. Outcomes were BMC at the whole body less head (WBLH) and lumbar spine (LS) and serum concentrations of 25-hydroxyvitamin D3 (25[OH]D3), parathyroid hormone (PTH) and bone turnover markers. Incidence of fractures was an outcome of the main trial.FINDINGS 1682 children were enrolled in the main trial, of whom 450 also participated in the sub-study. Among sub-study participants, end-trial serum 25(OH)D3 concentrations were higher for participants allocated to vitamin D vs. placebo (adjusted mean difference [aMD] 39.9 nmol/L, 95% CI 36.1 to 43.6, P<0.001) and serum PTH concentrations were lower (aMD -0.55 pmol/L, 95% CI -0.94 to -0.17, P=0.005). However, no interarm differences were seen for WBLH BMC (aMD -8.0 g, 95% CI - 30.7 to 14.7) or LS BMC (aMD -0.3 g, 95% CI -1.3 to 0.8), or for serum concentrations of bone turnover markers (P≥0.28). In the main trial, allocation did not influence fracture risk (adjusted odds ratio 0.70, 95% CI 0.27 to 1.85, P=0.48).INTERPRETATION Weekly vitamin D supplementation elevated serum 25(OH)D3 concentrations and suppressed serum PTH concentrations in HIV-uninfected schoolchildren of Black African ancestry but did not influence BMC, bone turnover markers or fracture risk.FUNDING Medical Research CouncilEVIDENCE BEFORE THIS STUDY We searched PubMed from inception to 31st December 2022 for randomised controlled trials (RCT) evaluating effects of vitamin D supplementation on bone mineral content (BMC), bone mineral density (BMD) and fracture risk in HIV-uninfected schoolchildren. A meta-analysis of data from 884 participants in six RCT reported no statistically significant effects of vitamin D on total body BMC, hip BMD, or forearm BMD, but a trend towards a small positive effect on lumbar spine BMD. RCT investigating fracture outcomes in HIV-uninfected children were lacking, as were RCT investigating effects of vitamin D on bone outcomes in HIV-uninfected children of Black African ancestry.ADDED VALUE OF THIS STUDY This is the first RCT to investigate effects of vitamin D supplementation on BMC and fracture risk in HIV-uninfected schoolchildren of Black African ancestry. We found that weekly oral supplementation with 10,000 IU vitamin D3 for 3 years elevated serum 25(OH)D3 concentrations and suppressed serum PTH concentrations, but did not influence serum concentrations of bone turnover markers, BMC at the whole body less head or lumbar spine sites, or fracture risk.IMPLICATIONS OF ALL THE AVAILABLE EVIDENCE Taken together with null findings from another recenty-completed phase 3 RCT of weekly oral vitamin D supplementation conducted in Mongolian schoolchildren, our findings do not support a role for vitamin D supplementation to increase BMC or reduce fracture risk in primary schoolchildren.Competing Interest StatementARM declares receipt of funding in the last 36 months to support vitamin D research from the following companies who manufacture or sell vitamin D supplements: Pharma Nord Ltd, DSM Nutritional Products Ltd, Thornton & Ross Ltd and Hyphens Pharma Ltd. ARM also declares receipt of vitamin D capsules for clinical trial use from Pharma Nord Ltd, Synergy Biologics Ltd and Cytoplan Ltd; support for attending meetings from Pharma Nord Ltd and Abiogen Pharma Ltd; receipt of consultancy fees from DSM Nutritional Products Ltd and Qiagen Ltd; receipt of a speaker fee from the Linus Pauling Institute; participation on Data and Safety Monitoring Boards for the VITALITY trial (Vitamin D for Adolescents with HIV to reduce musculoskeletal morbidity and immunopathology, Pan African Clinical Trials Registry ref PACTR20200989766029) and the Trial of Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India (ClinicalTrials.gov ref NCT04641195); and unpaid work as a Programme Committee member for the Vitamin D Workshop. All other authors declare that they have no competing interests.Clinical TrialNCT02880982Funding StatementThis study was funded by the UK Medical Research Council (refs MR/R023050/1 and MR/M026639/1)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial was approved by the University of Cape Town Faculty of Health Sciences Human Research Ethics Committee (Ref: 796/2015) and the London School of Hygiene and Tropical Medicine Observational/Interventions Research Ethics Committee (Ref: 7450-2)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAnonymised data may be requested from the corresponding author to be shared subject to terms of research ethics committee approval.